Oltipraz

奥替普拉

Report date: 2022/07/19 16:22:54

Base Information

Drug NameOltipraz
Drug Alias NameOltiprazumCB-1400RP-35972
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor erythroid 2-related factor 2 stimulants
TargetsNuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver DiseaseLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer IncSanofiCanopus
China Registration ClassN/A

Develop Information

Active CompaniesPharmaking
Inactive CompaniesNorthwestern UniversityHK inno.N Corporation
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsLiver CirrhosisLung Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia